KEY POINTS
- This retrospective study from Mass General Brigham Cancer Institute included 110 patients with locally advanced non-small cell lung cancer treated with definitive chemoradiotherapy followed by consolidation durvalumab between 2017 and 2022. Median age was 70.4 years, 56.4% had pre-existing cardiovascular disease, and median follow-up was 33.6 months. Investigators analyzed 3,729 heart-rate measurements, with a median of 36 measurements per patient.
- Definitive RT delivered a median 66 Gy, generally in 2-Gy fractions, with concurrent platinum-based chemotherapy. Heart and cardiac substructure doses were reconstructed using CT-based segmentation, including the sinoatrial node (SAN), atrioventricular node (AVN), cardiac chambers, and major vessels. Longitudinal resting heart rate was evaluated from pretreatment baseline through 12 months after RT, using generalized additive mixed models adjusted for clinical and treatment-related factors.
- Resting heart rate increased substantially during chemoradiotherapy. Median heart rate rose from approximately 80 bpm at baseline to 93 bpm near treatment completion, remaining approximately 95 bpm at one month after RT. Among 91 patients with evaluable baseline and end-of-treatment measurements, 76 (84%) demonstrated an increase, with a median individual change of +11 bpm (IQR 5–17; p<0.0001). Tachycardia episodes increased from 11.2% at baseline to 36.5% one month after treatment (p<0.0001).
- Higher mean dose to the SAN was consistently associated with greater heart-rate elevation, even after adjustment for cardiovascular comorbidities, chemotherapy, beta-blocker use, and anemia. The median mean SAN dose was 17.7 Gy, compared with 2.22 Gy for the AVN and 9.0 Gy for the whole heart. Across longitudinal models, SAN dose was associated with approximately 0.12–0.15 additional bpm per Gy, while mean whole-heart and AVN doses showed no consistent significant associations.
- Patients in the highest SAN dose tertile (>37.1 Gy) demonstrated more pronounced heart-rate elevation than those in the lowest tertile (<5.9 Gy). Adjusted differences averaged approximately +4.6 bpm during chemoradiotherapy, +8.7 bpm during recovery, and +6.6 bpm across the complete observation period. A higher SAN dose was also associated with earlier and more frequent tachycardia, although no prospectively validated SAN dose constraint was established.
- Clinically significant arrhythmias developed after chemoradiotherapy in 23 patients (20.9%), including 19 patients (17.3%) with de novo events. Tachycardia during week five was associated with increased odds of subsequent de novo arrhythmia (OR 2.97, 95% CI 1.17–7.52; p=0.022). An exploratory heart-rate increase >15 bpm during treatment was also associated with higher subsequent arrhythmia incidence (Gray's p=0.004), whereas smaller increases did not show the same association.
- Several potential confounders were investigated, including anemia, acute infection, radiation esophagitis, chemotherapy regimen, and durvalumab exposure, without materially explaining the SAN dose association. However, resting heart rate was collected during routine care rather than under standardized conditions, while ECG monitoring was symptom-driven rather than protocolized. The retrospective design, small number of arrhythmia events, and uncertainty in SAN contouring prevent causal inference or establishing a clinically actionable heart-rate threshold.
CLINICAL TAKEAWAY
Resting heart-rate elevation during thoracic chemoradiotherapy may provide an inexpensive signal of subsequent cardiac conduction abnormalities, with radiation dose to the sinoatrial node emerging as a potentially relevant planning parameter. These observational results support prospective evaluation of routine pulse monitoring and cardiac substructure sparing, but neither an intervention threshold nor a reduction in arrhythmia risk through SAN dose minimization has been demonstrated.
SOURCE
International Journal of Radiation Oncology, Biology, Physics